RPS17

Across TCGA pan-cancer cohorts, RPS17 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPS17 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RPS17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS17 expression acts as an unfavorable survival marker.

LUSC and COAD are the cancer types where RPS17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.043	0.819	<.001	18	view →
COAD	OS	Median	All	0.168	0.799	.004	15	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPS17–LUSC (OS)

Open the LUSC breakdown →